share_log

Head-To-Head Survey: JATT Acquisition (NYSE:JATT) Versus Novavax (NASDAQ:NVAX)

Head-To-Head Survey: JATT Acquisition (NYSE:JATT) Versus Novavax (NASDAQ:NVAX)

正面交锋调查:JATT 收购(纽约证券交易所代码:JATT)与 Novavax(纳斯达克股票代码:NVAX)
Defense World ·  2022/09/26 14:11

JATT Acquisition (NYSE:JATT – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

JATT Acquisition(纽约证券交易所代码:JATT — 获取评级)和 Novavax(纳斯达克股票代码:NVAX — 获取评级)都是小型医疗公司,但哪家业务更好?我们将根据两家公司的股息、估值、分析师建议、机构所有权、风险、盈利能力和收益对比这两家公司。

Institutional & Insider Ownership

机构和内部所有权

44.8% of JATT Acquisition shares are owned by institutional investors. Comparatively, 42.6% of Novavax shares are owned by institutional investors. 2.1% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

JATT Acquision的44.8%的股份由机构投资者拥有。相比之下,Novavax有42.6%的股票由机构投资者持有。2.1%的Novavax股票由公司内部人士拥有。强大的机构所有权表明捐赠基金、大型基金经理和对冲基金认为股票有望实现长期增长。

Get
得到
JATT Acquisition
收购 JATT
alerts:
警报:

Profitability

盈利能力

This table compares JATT Acquisition and Novavax's net margins, return on equity and return on assets.

该表比较了JATT Acquisition和Novavax的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
JATT Acquisition N/A -105.35% 6.64%
Novavax -114.32% -572.54% -55.69%
净利润 股本回报率 资产回报率
收购 JATT 不适用 -105.35% 6.64%
Novavax -114.32% -572.54% -55.69%

Earnings & Valuation

收益与估值

This table compares JATT Acquisition and Novavax's top-line revenue, earnings per share and valuation.
该表比较了JATT Acquisition和Novavax的营收、每股收益和估值。
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
JATT Acquisition N/A N/A $6.85 million N/A N/A
Novavax $1.15 billion 1.43 -$1.74 billion ($19.46) -1.08
总收入 价格/销售比率 净收入 每股收益 市盈率
收购 JATT 不适用 不适用 685 万美元 不适用 不适用
Novavax 11.5 亿美元 1.43 -17.4 亿美元 (19.46 美元) -1.08

JATT Acquisition has higher earnings, but lower revenue than Novavax.

JATT Acquisition的收益更高,但收入低于Novavax。

Analyst Ratings

分析师评级

This is a summary of current ratings for JATT Acquisition and Novavax, as reported by MarketBeat.com.

这是Marketbeat.com报道的JATT Accusition和Novavax当前评级的摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JATT Acquisition 0 0 0 0 N/A
Novavax 2 0 5 0 2.43
卖出评级 持有评级 买入评级 强劲的买入评级 评分分数
收购 JATT 0 0 0 0 不适用
Novavax 2 0 5 0 2.43

Novavax has a consensus price target of $128.25, indicating a potential upside of 510.71%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than JATT Acquisition.

Novavax的共识目标股价为128.25美元,表明潜在的上涨空间为510.71%。鉴于Novavax可能有更高的上行空间,分析师显然认为Novavax比JATT收购更有利。

Summary

摘要

JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.

JATT Accusition在两只股票的9个因素中有5个击败了Novavax。

About JATT Acquisition

关于收购 JATT

(Get Rating)

(获取评级)

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

JATT 收购公司没有重大业务。它打算与一个或多个企业或实体进行合并、资本股份交换、资产收购、股份购买、重组或类似的业务合并。该公司打算专注于主要在生命科学领域运营的业务。JATT Acquisition Corp 于 2021 年成立,总部位于开曼群岛的大开曼岛。

About Novavax

关于 Novavax

(Get Rating)

(获取评级)

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc. 是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重传染病和满足健康需求。该公司的候选疫苗包括NVx-CoV2373,这是一种正在进行两项III期试验、一项IIb期试验和一项I/II期试验的冠状病毒候选疫苗;nanoFlu,一种正在进行三期临床试验的纳米颗粒季节性四价流感候选疫苗;以及呼吸道合胞病毒 (RSV) 融合 (F) 蛋白纳米颗粒候选疫苗ResVax。它还在开发RSV F疫苗,该疫苗已进入针对老年人(60岁及以上)的II期临床试验,也正在为儿科进行I期临床试验。它与武田制药有限公司签订了合作协议,用于开发、制造和商业化 COVID-19 候选疫苗 nvx-coV2373。Novavax, Inc. 成立于 1987 年,总部位于马里兰州盖瑟斯堡。

Receive News & Ratings for JATT Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JATT Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收收购 JATT 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收JATT Accuction及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发